Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 7SL, cytoplasmic 130, pseudogene (RN7SL130P) is classified as a pseudogene derived from the 7SL RNA family, a component sequence of the signal recognition particle (SRP) involved in the targeting of secretory proteins to the endoplasmic reticulum[1][6]. Pseudogenes such as RN7SL130P do not encode functional RNA or protein products and generally lack biological function, arising from the reverse transcription of 7SL RNA and subsequent genomic integration[6]. There is no evidence to indicate that RN7SL130P is expressed or plays any therapeutic, biological, or pathological role; it is not considered a therapeutic target, a biomarker, or associated with any disease[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 130, pseudogene (RN7SL130P).